NCT05919069CompletedPhase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of AZD2693.
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- First submitted
- 16 Jun 2023
- Start date
- 16 Jun 2023
- Primary completion date
- 16 Sept 2024
- Lead sponsor
- AstraZeneca
- NCT number
- NCT05919069
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 35
- From 16 Jun 2023 to the primary completion date, 16 Sept 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of any major surgical procedure within 30 days prior to study intervention
Other illness
- Positive test for HIV at screening
- History or presence of clinically significant thyroid disease
- History or presence of clinically significant or unstable medical or psychiatric condition
Lab values
- Participant with impaired hepatic function has eGFR \< 60 mL/minute/1.73 m2 and participant with normal hepatic function has eGFR \< 90 mL/minute/1.73 m2
Who the study is looking for
- For Hepatic:
- Participant with a diagnosis of chronic and stable hepatic impairment
- For Healthy:
- Participant with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or 12-lead ECGs,
- All participants:
- \- Body weight ≥ 50 kg; BMI within the range of 18.0 to 40.0 kg/m2 (inclusive) as measured at screening
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Miami Lakes | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Orlando | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Rialto | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.